Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech that has worked faithfully but unsuccessfully to create an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in phrases of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination therapy in the therapy of multi-drug-resistant HIV are actually closing.

I am composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the last few shares of mine. My 1st CytoDyn article, “CytoDyn: What To Do When It is Too Good To Be True?”, set away the following prediction:

Instead I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly marketing image in the Uptick Newswire interview which I came away with an inadequate viewpoint of the business.

Irony of irony, my bad impression of the company has grown steadily, yet the disappointment hasn’t been financial. 2 years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for the treatment as well as avoidance of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity in HIV infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this technology as well as linked intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and also the first new drug application approval ($5 million), and also royalty payments of 5 % of net sales after commercialization.

Since that time, CytoDyn’s guiding nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it has this single treatment as well as a “broad pipeline of indications” because it places it. I call such pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

Its opening banner on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, multiple disease types, multiple publications in addition to multiple presentations.

Could all of it be smoke and mirrors? That is a question I have been asking myself through the very start of my interest in this particular company. Judging with the multiples of a huge number of several remarks on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *